Use of interferon-α-induced dendritic cells in the therapy of patients with malignant brain gliomas

Bulletin of Experimental Biology and Medicine

Volumn 143, Issue 4, 2007, Pages 528-534

  Leplina, O Yu ^a   Stupak, V V ^b   Kozlov, Yu P ^b   Pendyurin, I V ^b   Nikonov, S D ^a   Tikhonova, M A ^a   Sycheva, N V ^a   Ostanin, A A ^a   Chernykh, E R ^a  

^a INSTITUTE OF CLINICAL IMMUNOLOGY   (Russian Federation)

^b NOVOSIBIRSK RESEARCH INSTITUTE OF TRAUMATOLOGY AND ORTHOPAEDICS N A YA L TSIVYAN   (Russian Federation)

Author keywords

Dendritic cells; Glioma; Immunotherapy

Indexed keywords

ALPHA INTERFERON; DENDRITIC CELL VACCINE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; RECOMBINANT INTERLEUKIN 2; RONCOLEUKIN; UNCLASSIFIED DRUG;

ADOLESCENT; ADOPTIVE IMMUNOTHERAPY; ADULT; AGED; ANTIGEN SPECIFICITY; ARTICLE; BRAIN RADIATION; BRAIN SURGERY; CANCER IMMUNIZATION; CANCER IMMUNOTHERAPY; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; GLIOMA; HUMAN; HUMAN CELL; MAJOR CLINICAL STUDY; MALE; QUALITY OF LIFE; UNSPECIFIED SIDE EFFECT;

ADOLESCENT; ADULT; AGED; BRAIN NEOPLASMS; DENDRITIC CELLS; FEMALE; FLOW CYTOMETRY; GLIOMA; HUMANS; IMMUNOPHENOTYPING; IMMUNOTHERAPY; IMMUNOTHERAPY, ADOPTIVE; INTERFERON-ALPHA; MALE; MIDDLE AGED; PILOT PROJECTS; QUALITY OF LIFE; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 34648840808     PISSN: 00074888     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10517-007-0172-1     Document Type: Article

References (23)

1. O. Yu. Leplina, M. A. Tikhonova, Yu. P. Kozlov, et al., Med. Immunol., 7, No. 4, 365-374 (2005).
2. V. P. Lozovoi and V. S. Kozhevnikov, Methods for Evaluating Cellular Effector Functions of Delayed-Type hypersensitivity. Methodological Recommendations [in Russian], Moscow (1990), pp. 1-10.
3. A. A. Ostanin, M. I. Tsentner, N. A. Khonina, et al., Vopr. Onkol., 49, No. 2, 170-175 (2003).
4. E. R. Chernykh, V. V. Stupak, M. I. Tsentner, et al., Med. Immunol., 4, Nos. 4-5, 588-592 (2002).
5. E. R. Chernykh, V. V. Stupak, M. I. Tsentner, et al., Sibirsk. Onkol. Zh., Nos. 2-3, 85-88 (2004).
6. Y. Akasaki, T. Kikuchi, S. Homma, et al., J. Immunother., 24, No. 2, 106-113 (2001).
7. J. Banchereau and R. M. Steinman, Nature, 392, 245-252 (1998).
8. S. Della Bella, S. Nicola, A. Riva, et al., J. Leukoc. Biol., 75, No. 1, 106-116 (2004).
9. R. A. Feinstermaker and M. J. Ciesielski, Cancer Control, 11, No. 3, 181-190 (2004).
10. T. Kikuchi, Y. Akasaki, M. Irie, et al., Cancer Immunol. Immunother., 50, No. 7, 337-344 (2001).
11. M. F. Lipscomb and B. J. Masten, Physiol. Rev., 82, No. 1, 97-130 (2002).
12. S. Parlato, S. M. Santini, C. Lapenta, et al., Blood, 98, No. 10, 3022-3029 (2001).
13. W. F. Pickl, O. Majdic, P. Kohl, et al., J. Immunol., 157, No. 9, 3850-3859 (1996).
14. S. M. Santini, C. Lapenta, M. Logozzi, et al., J. Exp. Med., 191, No. 10, 1777-1788 (2000).
15. S. M. Santini, T. Di Pucchio, C. Lapenta, et al., Stem Cells, 21, No. 3, 357-362 (2003).
16. S. M. Santini and F. Belardelli, Ibid., 21, No. 4, 495-505 (2003).
17. S. A. Soling and N. G. Rainov, Mol. Med., 7, No. 10, 659-667 (2001).
18. B. Thurner, C. Roder, D. Dieckmann, et al., J. Immunol. Methods, 223, No. 1, 1-15 (1999).
19. B. A. Tjoa and M. L. Salgaller, Expert Opin. Investig. Drugs, 9, No. 9, 2093-2102 (2000).
20. R. Yamanaka, J. Homma, N. Yajima, et al., Clin. Cancer Res., 11, No. 11, 4160-4167 (2005).
21. R. Yamanaka, N. Yajima, T. Abe, et al., Int. J. Oncol., 23, No. 1, 5-15 (2003).
22. S. Yoshida, K. Morii, M. Watanabe, et al., Cancer Immunol. Immunother., 50, No. 6, 321-327 (2001).
23. J. S. Yu, C. J. Wheeler, P. M. Zeltzer, et al., Cancer Res., 61, No. 3, 842-847 (2001).